The Food and Drug Administration granted Fast Track designation to aTyr Pharma Inc.'s (Nasdaq: LIFE) limb girdle muscular dystrophy treatment Resolaris. Shares of the biotherapeutics company climbed 80 cents to close at $3.25.
Fast Track designation granted to aTyr Pharma
January 18, 2017 at 16:16 PM EST